Hereditary Angioedema — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Hereditary Angioedema.
Regis Jefferson et al. — Cardiology in review (25 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41860288/
- 2.
Advances in hereditary angioedema in the modern treatment era in China: a focus on diagnosis, treatment, and prognosis.
Zhao Ye et al. — Orphanet journal of rare diseases (20 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41862921/
- 3.
Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial.
Maurer Marcus et al. — The Lancet. Haematology (19 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41865747/
- 4.
Oral deucrictibant for prophylaxis of hereditary angioedema attacks (CHAPTER-1): primary analysis of a randomised, double-blind, placebo-controlled, phase 2 trial.
Aygören-Pürsün Emel et al. — The Lancet. Haematology (19 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41865746/
- 5.
Unearthing Hereditary Angioedema in India-Epidemiology From Chandigarh and Reasi, India.
Jindal Ankur K et al. — Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (19 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41853845/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Recruiting — Phase 3 — Stemline Therapeutics, Inc.
https://clinicaltrials.gov/study/NCT06492616
- 2.
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Recruiting — Phase 1 — Yuhan Corporation
https://clinicaltrials.gov/study/NCT05523947
- 3.
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting — Phase 3 — Pharvaris Netherlands B.V.
https://clinicaltrials.gov/study/NCT06679881
- 4.
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
Recruiting — CHDI Foundation, Inc.
https://clinicaltrials.gov/study/NCT01574053
- 5.
A Study of Navenibart in Participants With Hereditary Angioedema
Recruiting — Phase 3 — Astria Therapeutics, Inc.
https://clinicaltrials.gov/study/NCT06842823
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Hereditary Angioedema
Hereditary angioedema is a rare genetic condition causing recurrent episodes of severe swelling in the skin, abdomen, and airway. It is caused by deficiency or dysfunction of C1 inhibitor. Untreated attacks can be life-threatening. Effective preventive and on-demand treatments are now available on the PBS.
Most Recent Research
Hereditary angioedema is a rare and disabling disorder caused by mutations in the SERPING1 gene. These mutations ultimately lead to deficient or dysfunctional C1 esterase inhibitor and unregulated activation of the kallikrein-kinin system. This review discusses the current epidemiology, etiology, and pathophysiology of the disorder and highlights how advances in our understanding have reframed diagnostic and therapeutic strategies. We further delineate the roles of classical, alternative, and lectin complement pathways in hereditary angioedema's pathophysiology and discuss C1 esterase inhibitor within the broader serpin family context. We discuss implications for clinical practice, including diagnostic workups, genetic considerations, and targeted therapies that modulate the bradykinin pathway, aiming to shorten diagnostic timelines and optimize patient outcomes.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.